Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of 20vPnC in Healthy Children 15 Months to 17 Years
NCT04642079Phase 3Completed
- Sponsor
- Pfizer
- Start
- Dec 2020
- Primary completion
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Prevnar 20 in pneumococcal disease, sponsored by Pfizer. Started Dec 2020; status: completed.
02
Drugs
Prevnar 20
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT04642079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04642079.